{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:56:44Z","timestamp":1792000604679,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ejpb.2019.05.020","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T08:37:25Z","timestamp":1558514245000},"page":"130-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs"],"prefix":"10.1016","volume":"141","author":[{"given":"Talia","family":"Flanagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2019.05.020_b0005","unstructured":"US FDA Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2017."},{"key":"10.1016\/j.ejpb.2019.05.020_b0010","unstructured":"EMA Guideline on the investigation of bioequivalence (CPMP\/QWP\/EWP\/1401\/98 Rev. 1, 2010)."},{"key":"10.1016\/j.ejpb.2019.05.020_b0015","unstructured":"Health Canada Guidance Document: Biopharmaceutics Classification System Based Biowaiver, 2014."},{"key":"10.1016\/j.ejpb.2019.05.020_b0020","unstructured":"ICH Final endorsed Concept Paper M9: Biopharmaceutics Classification System-based Biowaivers, 7 October 2016. <http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Multidisciplinary\/M9\/ICH_M9_Concept_paper-final_7Oct2016.pdf>."},{"key":"10.1016\/j.ejpb.2019.05.020_b0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejps.2014.02.010","article-title":"In vivo methods for drug absorption \u2013 comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation\/API\/excipient characterization including food effects","volume":"57","author":"Sj\u00f6gren","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejpb.2019.05.020_b0030","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1208\/s12248-016-9928-8","article-title":"The effects of pharmaceutical excipients on gastrointestinal tract metabolic enzymes and transporters-an update","volume":"18","author":"Zhang","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2019.05.020_b0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejps.2014.09.004","article-title":"Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence","volume":"65","author":"Garc\u00eda-Arieta","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejpb.2019.05.020_b0040","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1053\/j.gastro.2007.06.060","article-title":"Free fatty acids have more potent effects on gastric emptying, gut hormones, and appetite than triacylglycerides","volume":"133","author":"Little","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ejpb.2019.05.020_b0045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1023\/A:1016256619309","article-title":"The effect of different concentrations of mannitol in solution on small intestinal transit: implications for drug absorption","volume":"12","author":"Adkin","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.05.020_b0050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2125.1995.tb04466.x","article-title":"The effects of pharmaceutical excipients on small intestinal transit","volume":"39","author":"Adkin","year":"1995","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejpb.2019.05.020_b0055","first-page":"393","article-title":"The effect of mannitol on the oral bioavailability of cimetidine","volume":"2","author":"Adkin","year":"1995","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.ejpb.2019.05.020_b0060","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1023\/B:PHAM.0000008046.64409.bd","article-title":"Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption","volume":"20","author":"Schulze","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.05.020_b0065","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1023\/A:1018918907670","article-title":"Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time","volume":"10","author":"Koch","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.05.020_b0070","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s11095-008-9635-y","article-title":"Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females","volume":"25","author":"Ashiru","year":"2008","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.ejpb.2019.05.020_b0075","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/ajcn\/49.6.1228","article-title":"Xylitol vs glucose: effect on the rate of gastric emptying and motilin, insulin, and gastric inhibitory polypeptide release","volume":"49","author":"Salminen","year":"1989","journal-title":"Am. J. Clin. Nutr."},{"issue":"10","key":"10.1016\/j.ejpb.2019.05.020_b0080","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/gut.23.10.824","article-title":"Is the transit time of a meal through the small intestine related to the rate at which it leaves the stomach?","volume":"23","author":"Read","year":"1982","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejpb.2019.05.020_b0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11095-006-9120-4","article-title":"A modern view of excipient effects on bioequivalence: case study of sorbitol","volume":"24","author":"Chen","year":"2007","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2019.05.020_b0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1021\/mp800261a","article-title":"Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment","volume":"6","author":"Tannergren","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2019.05.020_b0095","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1023\/A:1018827030210","article-title":"The effect of oleic acid on the human ileal brake and its implications for small intestinal transit of tablet formulations","volume":"16","author":"Dobson","year":"1999","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.ejpb.2019.05.020_b0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5414\/CPP45293","article-title":"Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets","volume":"45","author":"van Os","year":"2007","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.ejpb.2019.05.020_b0105","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/jps.1127","article-title":"Effect of common excipients on Caco-2 transport of low-permeability drugs","volume":"90","author":"Rege","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.05.020_b0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11095-015-1773-4","article-title":"The effects of excipients on the permeability of BCS Class 3 compounds and implications for biowaivers","volume":"33","author":"Parr","year":"2016","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.ejpb.2019.05.020_b0115","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1021\/acs.molpharmaceut.7b00353","article-title":"Preclinical effect of absorption modifying excipients on rat intestinal transport of model compounds and the mucosal barrier marker 51Cr-EDTA","volume":"14","author":"Dahlgren","year":"2017","journal-title":"Mol. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2019.05.020_b0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.05.029","article-title":"The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs","volume":"547","author":"Dahlgren","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.ejpb.2019.05.020_b0125","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1002\/jps.10491","article-title":"Enhanced intestinal absorption of drugs by activation of peptide transporter PEPT1 using proton-releasing polymer","volume":"92","author":"Nozawa","year":"2003","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2019.05.020_b0130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0009-9236(03)00059-6","article-title":"Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40","volume":"73","author":"Tayrouz","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejpb.2019.05.020_b0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/0973-8398.154688","article-title":"Influence of excipients on drug absorption via modulation of intestinal transporters activity","volume":"9","author":"Hetal","year":"2015","journal-title":"Asian J. Pharm."},{"key":"10.1016\/j.ejpb.2019.05.020_b0140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijpharm.2011.02.059","article-title":"The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers","volume":"409","author":"Ashiru-Oredope","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2019.05.020_b0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clpt.2004.09.001","article-title":"P-glycoprotein and surfactants: effect on intestinal talinolol absorption","volume":"77","author":"Bogman","year":"2005","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.ejpb.2019.05.020_b0150","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejps.2008.11.002","article-title":"Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo","volume":"36","author":"Ren","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2019.05.020_b0155","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jps.24643","article-title":"Effect of common excipients on the oral drug absorption of biopharmaceutics classification system class 3 drugs cimetidine and acyclovir","volume":"105","author":"Vaithianathan","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2019.05.020_b0160","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1208\/s12249-012-9814-3","article-title":"Developing in vitro-in vivo correlation of risperidone immediate release tablet","volume":"13","author":"Saibi","year":"2012","journal-title":"AAPS Pharm. Sci. Tech."},{"issue":"61","key":"10.1016\/j.ejpb.2019.05.020_b0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejps.2014.03.008","article-title":"Novel insights into excipient effects on the biopharmaceutics of APIs from different BCS classes: lactose in solid oral dosage forms","volume":"30","author":"Kubbinga","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.ejpb.2019.05.020_b0170","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1023\/A:1016473601633","article-title":"Biopharmaceutics classification system: the scientific basis for biowaiver extensions","volume":"19","author":"Yu","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.05.020_b0175","unstructured":"FDA Guidance for Industry, Immediate Release Solid Oral Dosage Forms \u2013 Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation, 1995."},{"key":"10.1016\/j.ejpb.2019.05.020_b0180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cmpb.2016.11.006","article-title":"Biopharmaceutics data management system for anonymised data sharing and curation: first application with orbito IMI project","volume":"140","author":"Lacy-Jones","year":"2017","journal-title":"Comput. Methods Programs Biomed."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117314923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117314923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:33:42Z","timestamp":1760546022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641117314923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":36,"alternative-id":["S0939641117314923"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.05.020","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}